The management of type 2 diabetes mellitus (T2DM) has witnessed a treatment paradigm in the light of recent cardiovascular outcomes trials (CVOTs) which have placed more emphasis on cardiovascular risk reduction than on glycemic control. Interestingly, drugs that did not reduce cardiovascular risk are considered suitable for populations with lower cardiovascular risk by the most esteemed world guidelines [1]. This statement may lack high-quality evidence, as none of the studies so far have focused on the comparison of the cardiovascular risk profiles of the included trial population.
